tradingkey.logo

Exact Sciences Corp

EXAS
View Detailed Chart
62.740USD
-0.560-0.88%
Close 10/29, 16:00ETQuotes delayed by 15 min
11.87BMarket Cap
LossP/E TTM

Exact Sciences Corp

62.740
-0.560-0.88%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.88%

5 Days

-0.27%

1 Month

+17.53%

6 Months

+40.08%

Year to Date

+11.66%

1 Year

-9.91%

View Detailed Chart

TradingKey Stock Score of Exact Sciences Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exact Sciences Corp's Score

Industry at a Glance

Industry Ranking
11 / 407
Overall Ranking
64 / 4623
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 24 analysts
Buy
Current Rating
69.815
Target Price
+10.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Exact Sciences Corp Highlights

StrengthsRisks
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.37% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.76B.
Fairly Valued
The company’s latest PE is -11.53, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 181.01M shares, decreasing 9.98% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 52.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.52.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Exact Sciences Corp Info

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Ticker SymbolEXAS
CompanyExact Sciences Corp
CEOMr. Kevin T. Conroy
Websitehttps://www.exactsciences.com/
KeyAI